JNJ241115P130000
- 0.02
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High...
Express News | Nipocalimab Is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living With Moderate-to-Severe Sjögren's Disease
Express News | Stand up to Cancer Collaborates With Johnson & Johnson to Explore Targeted Therapies for Rare Disease Linked to Blood Cancers
STAND UP TO CANCER COLLABORATES WITH JOHNSON & JOHNSON TO EXPLORE TARGETED THERAPIES FOR RARE DISEASE LINKED TO BLOOD CANCERS
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With Johnson & Johnson (NYSE:JNJ) It Looks Like You'll Get What You Pay For
Express News | Johnson & Johnson Submits Applications in the U.S. and EU Seeking Approval of Darzalex Faspro® / Darzalex® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma
Express News | shanghai Municipal Medical Insurance Bureau organizes centralized procurement of pharmaceuticals and high-value consumables exceeding 2 billion yuan
J&J Wins Approval of Varipulse Atrial Fibrillation Device
Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry
Band-Aid, Tylenol Parent's Sales Miss the Mark Amid Weakness in Skin Health
Express News | Johnson & Johnson Medtech Receives FDA Approval for Varipulse™ Pulsed Field Ablation Platform for Treatment of Atrial Fibrillation
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Johnson & Johnson Analyst Ratings
Why Most Healthcare Stocks Are Falling With Trump's Win, With Some Exceptions
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $162
Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating
Express News | Global first BCMA x CD3 bispecific drug Tlachol is launched in China.
Johnson & Johnson (JNJ.US) monoclonal antibody therapy achieves Phase 3 clinical primary endpoints significantly delaying high-risk SMM progression.
The American Society of Hematology (ASH) released abstracts of some studies at its 2024 conference.